Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against Pathogens Harboring OXA-48 and AmpC Alone or in Combination with Other β-Lactamases Collected from Phase 3 Clinical Trials and an International Surveillance Program-Reference-Cited by-同舟云学术

Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against Pathogens Harboring OXA-48 and AmpC Alone or in Combination with Other β-Lactamases Collected from Phase 3 Clinical Trials and an International Surveillance Program

Published:2022-03-15 Issue:3 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Lin Lynn-Yao¹^ORCID,Debabov Dmitri¹,Chang William¹,Stone Gregory²,Riccobene Todd³

Affiliation:

1. Non-Clinical Development & Translational Sciences, AbbVie Inc., Irvine, California, USA

2. Pfizer Inc., Groton, Connecticut, USA

3. U.S. Medical Affairs, Research & Development, AbbVie Inc., Madison, New Jersey, USA

Abstract

In vitro activities of ceftazidime-avibactam (CAZ-AVI) and key comparators against AmpC-overproducing Enterobacterales and P. aeruginosa isolates from four Phase 3 clinical trials and against OXA-48-producing Enterobacterales with multiple resistance mechanisms from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, were evaluated. Susceptibility to CAZ-AVI and comparators was determined by reference broth microdilution methods.

Funder

Abbvie Inc

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01985-21

Reference25 articles.

1. OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs

2. Is Ceftazidime/Avibactam an Option for Serious Infections Due to Extended-Spectrum-β-Lactamase- and AmpC-Producing Enterobacterales ?: a Systematic Review and Meta-analysis

3. OXA-48-Like-Producing Klebsiella pneumoniae in Southern Spain in 2014–2015

4. Treatment of Infections by OXA-48-Producing Enterobacteriaceae

5. Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination Therapy for OXA-48 Carbapenemase-Producing Klebsiella Pneumoniae Bloodstream Infections in Premature Infant: A Case Report and Literature Review;Infection and Drug Resistance;2024-05

2. Efficacy and safety of ceftazidime/avibactam in patients with infections caused by β-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme;Journal of Antimicrobial Chemotherapy;2023-09-13

3. The primary pharmacology of ceftazidime/avibactam: microbiology from clinical studies, and development of resistance during treatment;Journal of Antimicrobial Chemotherapy;2023-03-08

4. In Vitro Activity of Ceftolozane-Tazobactam against Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa Obtained from Blood Cultures from Sentinel Public Hospitals in South Africa;Antibiotics;2023-02-24